G I Papakostas

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): a pooled analysis of 10 studies
    George I Papakostas
    Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychiatry 69:1287-92. 2008
  2. ncbi Serum prolactin levels among outpatients with major depressive disorder during the acute phase of treatment with fluoxetine
    George I Papakostas
    Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychiatry 67:952-7. 2006
  3. doi Assessment of a multi-assay, serum-based biological diagnostic test for major depressive disorder: a pilot and replication study
    G I Papakostas
    Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Mol Psychiatry 18:332-9. 2013
  4. doi L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials
    George I Papakostas
    Center for Treatment Resistant Depression, Depression Clinical and Research Program, The Biostatistics Center, and the Clinical Trials Network and Institute, Massachusetts General Hospital, Boston, MA, USA
    Am J Psychiatry 169:1267-74. 2012
  5. ncbi Folates and S-adenosylmethionine for major depressive disorder
    George I Papakostas
    Harvard Medical School and Director of Center for Treatment Resistant Depression, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
    Can J Psychiatry 57:406-13. 2012
  6. doi A 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial of ziprasidone as monotherapy for major depressive disorder
    George I Papakostas
    Center for Treatment Resistant Depression, Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychiatry 73:1541-7. 2012
  7. doi Surrogate markers of treatment outcome in major depressive disorder
    George I Papakostas
    Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, One Bowdoin Square, Boston, MA 02114, USA
    Int J Neuropsychopharmacol 15:841-54. 2012
  8. doi Severe and anxious depression: combining definitions of clinical sub-types to identify patients differentially responsive to selective serotonin reuptake inhibitors
    George I Papakostas
    Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Eur Neuropsychopharmacol 22:347-55. 2012
  9. pmc Residual sleep disturbance and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine
    Huaiyu Yang
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    Ann Gen Psychiatry 9:10. 2010
  10. doi Simultaneous initiation (coinitiation) of pharmacotherapy with triiodothyronine and a selective serotonin reuptake inhibitor for major depressive disorder: a quantitative synthesis of double-blind studies
    George I Papakostas
    Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Int Clin Psychopharmacol 24:19-25. 2009

Detail Information

Publications92

  1. ncbi Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): a pooled analysis of 10 studies
    George I Papakostas
    Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychiatry 69:1287-92. 2008
    ....
  2. ncbi Serum prolactin levels among outpatients with major depressive disorder during the acute phase of treatment with fluoxetine
    George I Papakostas
    Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychiatry 67:952-7. 2006
    ..To determine changes in serum prolactin levels in outpatients with DSM-IV-diagnosed major depressive disorder (MDD) following a 12-week open-label trial of fluoxetine...
  3. doi Assessment of a multi-assay, serum-based biological diagnostic test for major depressive disorder: a pilot and replication study
    G I Papakostas
    Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Mol Psychiatry 18:332-9. 2013
    ..Further research is needed to confirm the performance of the test across various age and ethnic groups, and in different clinical settings...
  4. doi L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials
    George I Papakostas
    Center for Treatment Resistant Depression, Depression Clinical and Research Program, The Biostatistics Center, and the Clinical Trials Network and Institute, Massachusetts General Hospital, Boston, MA, USA
    Am J Psychiatry 169:1267-74. 2012
    ....
  5. ncbi Folates and S-adenosylmethionine for major depressive disorder
    George I Papakostas
    Harvard Medical School and Director of Center for Treatment Resistant Depression, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
    Can J Psychiatry 57:406-13. 2012
    ..Although further randomized controlled trials in this area appear warranted, SAMe and L-methylfolate may represent a useful addition to the AD armamentarium...
  6. doi A 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial of ziprasidone as monotherapy for major depressive disorder
    George I Papakostas
    Center for Treatment Resistant Depression, Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychiatry 73:1541-7. 2012
    ..To study ziprasidone monotherapy for major depressive disorder, defined according to the DSM-IV...
  7. doi Surrogate markers of treatment outcome in major depressive disorder
    George I Papakostas
    Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, One Bowdoin Square, Boston, MA 02114, USA
    Int J Neuropsychopharmacol 15:841-54. 2012
    ..The purpose of this work is to focus selectively on areas where there have been findings, as opposed to conducting an exhaustive literature review of studies which have failed to yield any significant breakthrough in our knowledge...
  8. doi Severe and anxious depression: combining definitions of clinical sub-types to identify patients differentially responsive to selective serotonin reuptake inhibitors
    George I Papakostas
    Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Eur Neuropsychopharmacol 22:347-55. 2012
    ..These findings are preliminary, of yet undetermined clinical relevance, and warrant replication and further exploration...
  9. pmc Residual sleep disturbance and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine
    Huaiyu Yang
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    Ann Gen Psychiatry 9:10. 2010
    ..Future studies are needed to further explore the relationship between residual sleep disturbance and relapse in MDD. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00427128...
  10. doi Simultaneous initiation (coinitiation) of pharmacotherapy with triiodothyronine and a selective serotonin reuptake inhibitor for major depressive disorder: a quantitative synthesis of double-blind studies
    George I Papakostas
    Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Int Clin Psychopharmacol 24:19-25. 2009
    ..Clearly, further work is needed to help determine whether there are specific MDD populations that can, indeed, benefit from T3-SSRI coinitiation therapy...
  11. ncbi Antidepressant dose reduction and the risk of relapse in major depressive disorder
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, Mass 02114, USA
    Psychother Psychosom 76:266-70. 2007
    ....
  12. ncbi A meta-analysis of clinical trials comparing reboxetine, a norepinephrine reuptake inhibitor, with selective serotonin reuptake inhibitors for the treatment of major depressive disorder
    George I Papakostas
    Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, 15 Parkman Street, WAC 812 Boston, MA 02114, USA
    Eur Neuropsychopharmacol 18:122-7. 2008
    ..These results suggest that the NRI reboxetine and the SSRIs differ with respect to their side-effect profile and overall tolerability but not their efficacy in treating MDD...
  13. ncbi Limitations of contemporary antidepressants: tolerability
    George I Papakostas
    Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychiatry 68:11-7. 2007
    ....
  14. ncbi Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches
    George I Papakostas
    Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Biol Psychiatry 63:699-704. 2008
    ..The goal of the present work was to conduct a meta-analysis of studies comparing these two switch strategies...
  15. ncbi Comparing the rapidity of response during treatment of major depressive disorder with bupropion and the SSRIs: a pooled survival analysis of 7 double-blind, randomized clinical trials
    George I Papakostas
    Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychiatry 68:1907-12. 2007
    ..The current analysis was undertaken to determine if these antidepressants differ in rapidity of clinical effect...
  16. ncbi Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of anxiety symptoms in major depressive disorder: a meta-analysis of individual patient data from 10 double-blind, randomized clinical trials
    George I Papakostas
    Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    J Psychiatr Res 42:134-40. 2008
    ..09, p=0.569), or HAM-A scores at endpoint (3.30+/-2.89 vs. 3.31+/-2.89, p=0.552). Contrary to clinician impression, there does not appear to be any difference in the anxiolytic efficacy of bupropion and the SSRIs when used to treat MDD...
  17. ncbi Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychiatry 68:826-31. 2007
    ..To examine the efficacy and overall tolerability of augmentation of standard antidepressants with atypical antipsychotic agents for treatment-resistant major depressive disorder...
  18. ncbi Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents
    George I Papakostas
    Massachusetts General Hospital, Harvard Medical School, 15 Parkman Street, Boston, MA 02114, USA
    Biol Psychiatry 62:1217-27. 2007
    ..The goal of our work was to compare response rates among patients with MDD treated with either of these two broad categories of antidepressant drugs...
  19. ncbi Relative antidepressant efficacy of bupropion and the selective serotonin reuptake inhibitors in major depressive disorder: gender-age interactions
    George I Papakostas
    Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Int Clin Psychopharmacol 22:226-9. 2007
    ..This finding could, however, not be replicated when improvement in anxious/somatic symptoms was defined as a continuous measure...
  20. ncbi Hopelessness as a predictor of non-response to fluoxetine in major depressive disorder
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School Boston, MA 02114, USA
    Ann Clin Psychiatry 19:5-8. 2007
    ..The purpose of this study was to study hopelessness as a predictor of response to fluoxetine in outpatients with Major Depressive Disorder (MDD)...
  21. ncbi A meta-analysis of clinical trials comparing the serotonin (5HT)-2 receptor antagonists trazodone and nefazodone with selective serotonin reuptake inhibitors for the treatment of major depressive disorder
    George I Papakostas
    Department of Psychiatry, Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, 15 Parkman Street, WAC 812, Boston, MA 02114, USA
    Eur Psychiatry 22:444-7. 2007
    ..To compare response rates among patients with major depressive disorder (MDD) treated with either a serotonin-2 (5HT2-) receptor antagonist or a selective serotonin reuptake inhibitor (SSRI)...
  22. ncbi A metaanalysis of clinical trials comparing moclobemide with selective serotonin reuptake inhibitors for the treatment of major depressive disorder
    George I Papakostas
    Department of Psychiatry, Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Can J Psychiatry 51:783-90. 2006
    ....
  23. ncbi Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Psychiatry Res 149:195-200. 2007
    ..Further studies exploring the impact of various treatment modalities and placebo on the timing of clinical improvement and symptom resolution in MDD are warranted...
  24. ncbi Resolution of sleepiness and fatigue in major depressive disorder: A comparison of bupropion and the selective serotonin reuptake inhibitors
    George I Papakostas
    Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Biol Psychiatry 60:1350-5. 2006
    ....
  25. doi Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder. A replication of findings with the use of a double-blind, placebo-controlled trial of Hypericum perforatum versus fluoxetine
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, Mass 02114, USA
    Neuropsychobiology 56:132-7. 2007
    ..Thirty-nine MDD outpatients who responded following a 12-week, double-blind study comparing Hypericum perforatum, fluoxetine or placebo were included in the analysis...
  26. doi A meta-analysis of clinical trials comparing mirtazapine with selective serotonin reuptake inhibitors for the treatment of major depressive disorder
    G I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Department of Psychiatry, Boston, MA 02114, USA
    J Psychopharmacol 22:843-8. 2008
    ..8; 95% CI: 1.3-2.4; P < 0.0001) during the course of treatment. These results suggest that mirtazapine and the SSRIs differ with respect to their side-effect profile but not their overall efficacy in the treatment of MDD...
  27. ncbi Tolerability of modern antidepressants
    George I Papakostas
    Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, USA
    J Clin Psychiatry 69:8-13. 2008
    ....
  28. doi Testing anxious depression as a predictor and moderator of symptom improvement in major depressive disorder during treatment with escitalopram
    George I Papakostas
    Massachusetts General Hospital, Harvard Medical School, 15 Parkman Street, WACC 812, Boston, MA 02114, USA
    Eur Arch Psychiatry Clin Neurosci 261:147-56. 2011
    ..The present analysis did not support the notion that SNRIs are more effective than escitalopram in the treatment of anxious MDD, nor was there evidence to support treatment moderating effects for anxious MDD...
  29. doi S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial
    George I Papakostas
    Center for Treatment Resistant Depression, Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, 15 Parkman St, Boston, MA 02114, USA
    Am J Psychiatry 167:942-8. 2010
    ....
  30. doi The efficacy, tolerability, and safety of contemporary antidepressants
    George I Papakostas
    Department of Psychiatry, Harvard Medical School and Massachusetts General Hospital, Boston, MA 01224, USA
    J Clin Psychiatry 71:e03. 2010
    ..Finally, the safety profile of these agents is summarized...
  31. doi Are typical starting doses of the selective serotonin reuptake inhibitors sub-optimal? A meta-analysis of randomized, double-blind, placebo-controlled, dose-finding studies in major depressive disorder
    George I Papakostas
    Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    World J Biol Psychiatry 11:300-7. 2010
    ..Developing treatment strategies allowing clinicians to deliver higher initial SSRI doses while enhancing the tolerability of treatment may represent an alternative approach to improving the efficacy of treatment of MDD...
  32. ncbi Major depressive disorder: psychosocial impairment and key considerations in functional improvement
    George I Papakostas
    Treatment Resistant Depression Studies, Massachusetts General Hospital, Harvard Medical School, 15 Parkman St, WACC 812, Boston, MA 02114, USA
    Am J Manag Care 15:S316-21. 2009
    ....
  33. doi Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder
    George I Papakostas
    Department of Psychiatry, Harvard Medical School and Massachusetts General Hospital, Boston, MA 01224, USA
    J Clin Psychiatry 70:16-25. 2009
    ....
  34. doi Evidence for S-adenosyl-L-methionine (SAM-e) for the treatment of major depressive disorder
    George I Papakostas
    Department of Psychiatry, Harvard Medical School, Massachusetts General Hospital, 15 Parkman St WACC 812, Boston, MA 01224, USA
    J Clin Psychiatry 70:18-22. 2009
    ..Although preliminary data suggest SAM-e may be useful as an adjunctive therapy to antidepressants, controlled studies are needed to confirm or refute these preliminary findings...
  35. doi Fluoxetine-clonazepam cotherapy for anxious depression: an exploratory, post-hoc analysis of a randomized, double blind study
    George I Papakostas
    Depression Clinical and Research Program at Massachusetts General Hospital, Harvard Medical School, 15 Parkman Street, Boston, MA 02114, USA
    Int Clin Psychopharmacol 25:17-21. 2010
    ..The efficacy of fluoxetine-clonazepam cotherapy compared with fluoxetine monotherapy was numerically but not statistically enhanced for patients with anxious depression than those without anxious depression...
  36. doi 5HT1A-mediated stimulation of cortisol release in major depression: use of non-invasive cortisol measurements to predict clinical response
    George I Papakostas
    Harvard Medical School, Massachusetts General Hospital, 15 Parkman Street, Boston, MA 02114, USA
    Eur Arch Psychiatry Clin Neurosci 260:175-80. 2010
    ..Although the 5HT1A-desensitization hypothesis is still a valid one, the results of the present study could not provide any evidence in support...
  37. pmc Predictors, moderators, and mediators (correlates) of treatment outcome in major depressive disorder
    George I Papakostas
    Depression Clinical Research Program, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Dialogues Clin Neurosci 10:439-51. 2008
    ..Biologic leads will include gene polymorphisms, brain metabolism, quantitative electroencephalography, loudness dependence of auditory evoked potentials, and functional brain asymmetry...
  38. ncbi Use of atypical antipsychotics for treatment-resistant major depressive disorder
    George I Papakostas
    Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, 15 Parkman Street, WACC 812, Boston, MA 02114, USA
    Curr Psychiatry Rep 10:481-6. 2008
    ..This review summarizes the existing data regarding the effectiveness of these medications in treating TRD, including biochemical rationale and clinical data...
  39. doi Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD
    George I Papakostas
    Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Eur Neuropsychopharmacol 19:34-40. 2009
    ..Fixed versus flexible dose design, trial duration and population age did not influence clinical trial outcome...
  40. doi Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder
    George I Papakostas
    Depression Clinical and Research Program at Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Psychiatry Res 161:116-20. 2008
    ..Studies examining whether specific treatment strategies are more effective than the selective serotonin reuptake inhibitors for MDD patients with high levels of co-morbid psychic and somatic anxiety symptoms are warranted...
  41. ncbi Somatic symptoms in treatment-resistant depression
    George I Papakostas
    Department of Psychiatry, Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Psychiatry Res 118:39-45. 2003
    ..The overwhelming majority of patients with TRD presented with somatic symptoms. In addition, a greater number of somatic symptoms during the screen visit placed patients at risk for further treatment resistance...
  42. ncbi Psychosocial functioning during the treatment of major depressive disorder with fluoxetine
    George I Papakostas
    Department of Psychiatry, Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychopharmacol 24:507-11. 2004
    ..Therefore, studying the impact of treatment on psychosocial functioning in MDD could help further improve the standard of care...
  43. ncbi Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 2: predictors of relapse during the continuation phase of pharmacotherapy
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychiatry 65:1096-8. 2004
    ....
  44. ncbi Anxiety and somatic symptoms as predictors of treatment-related adverse events in major depressive disorder
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, 15 Parkman Street, WACC 812, Boston, MA 02114, USA
    Psychiatry Res 126:287-90. 2004
    ..Pre-treatment anxiety was not related to the development of side effects...
  45. ncbi Somatic symptoms as predictors of time to onset of response to fluoxetine in major depressive disorder
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, 15 Parkman Street, WACC 812, Boston, MA 02214, USA
    J Clin Psychiatry 65:543-6. 2004
    ..In the present study we assessed the relationship between somatic symptoms and the time to onset of clinical response to fluoxetine in patients with major depressive disorder (MDD)...
  46. ncbi Cholesterol in mood and anxiety disorders: review of the literature and new hypotheses
    George I Papakostas
    Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, 15 Parkman Street, WACC 812, Boston, MA 02114, USA
    Eur Neuropsychopharmacol 14:135-42. 2004
    ..We then propose possible mechanisms that would account for the relationship between elevated cholesterol and treatment non-response in MDD...
  47. ncbi Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder
    George I Papakostas
    Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, 15 Parkman Street, WAC 812, Boston, MA 02114, USA
    J Clin Psychiatry 65:217-21. 2004
    ..The purpose of this study is to test this hypothesis in depressed outpatients who have not experienced significant clinical improvement following an adequate trial of a selective serotonin reuptake inhibitor (SSRI)...
  48. ncbi Treatment-related adverse events and outcome in a clinical trial of fluoxetine for major depressive disorder
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Ann Clin Psychiatry 15:187-92. 2003
    ..These findings failed to reveal any relationship between side effects and treatment outcome for patients with MDD enrolled in an 8-week, 20 mg, fixed dose, open trial of fluoxetine...
  49. ncbi Quality of life assessments in major depressive disorder: a review of the literature
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    Gen Hosp Psychiatry 26:13-7. 2004
    ..Exploring the impact of these modalities on psychosocial function and quality of life in MDD are necessary to help translate clinical response into restoration of psychosocial function and to thus further improve the standard of care...
  50. ncbi Psychiatric comorbidity as a predictor of clinical response to nortriptyline in treatment-resistant major depressive disorder
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, Mass 02114, USA
    J Clin Psychiatry 64:1357-61. 2003
    ..The purpose of this study was to test whether the presence of comorbid Axis I and Axis II disorders predicts clinical response to an open trial of nor-triptyline among patients with treatment-resistant depression...
  51. ncbi S-adenosyl-methionine in depression: a comprehensive review of the literature
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital, 15 Parkman Street, WACC 812, Boston, MA 02114, USA
    Curr Psychiatry Rep 5:460-6. 2003
    ..Finally, the authors propose a model that would explain the actions of SAMe in the central nervous system...
  52. ncbi A pilot, open study of sertraline in outpatients with treatment-resistant depression (TRD) or with a history of TRD who responded but later relapsed
    George I Papakostas
    Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, 156 Parkman Street, WACC 812, Boston, MA 02114, USA
    Int Clin Psychopharmacol 18:293-6. 2003
    ....
  53. ncbi Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 1: predictors of clinical response in fluoxetine-resistant depression
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychiatry 65:1090-5. 2004
    ....
  54. ncbi Axis III disorders in treatment-resistant major depressive disorder
    George I Papakostas
    Department of Psychiatry, Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, 15 Parkman Street, WAC 812, Boston, MA 02114, USA
    Psychiatry Res 118:183-8. 2003
    ..Thus, the present results cannot be generalized to such populations...
  55. ncbi Serum cholesterol and serotonergic function in major depressive disorder
    George I Papakostas
    Depression Clinical and Research Program, Department of Psychiatry, Harvard Medical School, Massachusetts General Hospital, 15 Parkman Street, WAC 812, Boston, MA 02114, USA
    Psychiatry Res 118:137-45. 2003
    ....
  56. ncbi Serum cholesterol in treatment-resistant depression
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Neuropsychobiology 47:146-51. 2003
    ....
  57. ncbi Obesity among outpatients with major depressive disorder
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital Harvard Medical School, Boston, MA 02114, USA
    Int J Neuropsychopharmacol 8:59-63. 2005
    ..Greater relative body weight, but not obesity, predicted non-response. In conclusion, greater relative body weight was found to place MDD outpatients at risk for fluoxetine resistance...
  58. ncbi The relationship between serum folate, vitamin B12, and homocysteine levels in major depressive disorder and the timing of improvement with fluoxetine
    George I Papakostas
    Department of Psychiatry, Depression Clinical and Research Program, Massachusetts General Hospital Harvard Medical School, Boston, MA 02114, USA
    Int J Neuropsychopharmacol 8:523-8. 2005
    ..05). In conclusion, low serum folate levels were found to be associated with a delayed onset of clinical improvement during treatment with fluoxetine in MDD by, on average, 1.5 wk...
  59. ncbi A description of next-step switching versus augmentation practices for outpatients with treatment-resistant major depressive disorder enrolled in an academic specialty clinic
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Ann Clin Psychiatry 17:161-5. 2005
    ....
  60. ncbi The combination of duloxetine and bupropion for treatment-resistant major depressive disorder
    George I Papakostas
    Department of Psychiatry, Depression Clinical and Research Program, Massachusetts General Hospital, Boston, 02114, USA
    Depress Anxiety 23:178-81. 2006
    ..Although preliminary, these results suggest a possible role for the combination of duloxetine and bupropion for TRD...
  61. ncbi A meta-analysis of clinical trials comparing milnacipran, a serotonin--norepinephrine reuptake inhibitor, with a selective serotonin reuptake inhibitor for the treatment of major depressive disorder
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital, Department of Psychiatry, 15 Parkman Street, WAC 812, Harvard Medical School, Boston, Massachusetts 02114, USA
    Eur Neuropsychopharmacol 17:32-6. 2007
    ....
  62. ncbi Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder
    George I Papakostas
    Department of Psychiatry, Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Psychiatry 66:1326-30. 2005
    ..The purpose of this study was to test this hypothesis in depressed outpatients who have not experienced significant clinical improvement following an adequate trial of a selective serotonin reuptake inhibitor (SSRI)...
  63. ncbi Adjunctive atomoxetine for residual fatigue in major depressive disorder
    George I Papakostas
    Department of Psychiatry, Depression Clinical and Research Program, Massachusetts General Hospital, 15 Parkman Street, WAC 812, Boston, MA 02114, United States
    J Psychiatr Res 40:370-3. 2006
    ..To assess the effectiveness and safety of atomoxetine as an adjunctive medication for residual fatigue in a naturalistic treatment setting...
  64. ncbi Dopaminergic-based pharmacotherapies for depression
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Eur Neuropsychopharmacol 16:391-402. 2006
    ..In the present article we will briefly review studies focusing on the role of dopamine in depression followed by a comprehensive review of pharmacotherapies for depression with pro-dopaminergic activity...
  65. doi Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder
    Richard C Shelton
    Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, TN, USA
    Acta Psychiatr Scand 117:253-9. 2008
    ..Atypical antipsychotics (AAPs) have been hypothesized to be beneficial in treatment-resistant depression (TRD). This paper will review a biochemical rationale and will summarize the data regarding the effectiveness of AAPs in TRD...
  66. ncbi Hopelessness and suicidal ideation in outpatients with treatment-resistant depression: prevalence and impact on treatment outcome
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, WACC 812, 15 Parkman Street, Boston, Massachusetts, 02114, USA
    J Nerv Ment Dis 191:444-9. 2003
    ..Furthermore, a full 6-week trial of NT, a relatively noradrenergic tricyclic antidepressant, may be particularly useful in patients who have failed to respond to several antidepressants and also report significant hopelessness...
  67. ncbi Escitalopram versus SNRI antidepressants in the acute treatment of major depressive disorder: integrative analysis of four double-blind, randomized clinical trials
    Susan G Kornstein
    Department of Psychiatry, Virginia Commonwealth University, Richmond, VA 23298 0710, USA
    CNS Spectr 14:326-33. 2009
    ..Recent data suggest that escitalopram may be more effective in severe depression than other selective serotonin reuptake inhibitors...
  68. ncbi A survey of prescribing preferences in the treatment of refractory depression: recent trends
    R Kornbluh
    McLean Hospital, Belmont, MA, USA
    Psychopharmacol Bull 35:150-6. 2001
    ..Further research is necessary to elucidate the factors that influence clinicians' reasoning for selecting one strategy over another...
  69. ncbi Continuation cognitive-behavioural therapy maintains attributional style improvement in depressed patients responding acutely to fluoxetine
    T Petersen
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA, USA
    Psychol Med 34:555-61. 2004
    ..The goal of this study was to examine whether CBT would help maintain attributional style changes experienced by patients during acute phase fluoxetine treatment...
  70. ncbi Switching to bupropion in fluoxetine-resistant major depressive disorder
    Maurizio Fava
    The Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Ann Clin Psychiatry 15:17-22. 2003
    ..Bupropion SR should be considered as a potential treatment for patients who remain depressed despite treatment with SSRIs..
  71. ncbi Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism
    Madhusmita Misra
    Neuroendocrine Unit, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Psychiatry 65:1607-18; quiz 1590, 1760-1. 2004
    ..Few reviews have thus far addressed this issue. We have consolidated information from studies that examined effects of psychiatric conditions and their treatment on bone metabolism...
  72. ncbi Behavioral and emotional disturbances in the offspring of depressed parents with anger attacks
    Jonathan E Alpert
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, Mass, USA
    Psychother Psychosom 72:102-6. 2003
    ..To examine the emotional and behavioral characteristics of the offspring of depressed parents with and without anger attacks...
  73. ncbi Brain white-matter hyperintensities and treatment outcome in major depressive disorder
    Dan V Iosifescu
    Massachusetts General Hospital, 50 Staniford Street, Suite 401, Boston, Massachusetts 02114, USA
    Br J Psychiatry 188:180-5. 2006
    ..An increased incidence of brain white-matter hyperintensities has been described in major depressive disorder, butthe impact of such hyperintensities on treatment outcome is still controversial...
  74. ncbi Brain MRI white matter hyperintensities and one-carbon cycle metabolism in non-geriatric outpatients with major depressive disorder (Part I)
    Dan V Iosifescu
    Massachusetts General Hospital, Department of Psychiatry, Depression Clinical and Research Program, Harvard Medical School, 15 Parkman Street, WACC 812, Boston, MA 02114, USA
    Psychiatry Res 140:291-9. 2005
    ..In light of the adverse impact of WMHs on a number of health-related outcomes later in life, hypofolatemia and hypertension may represent modifiable risk factors to prevent the occurrence of such adverse outcomes...
  75. ncbi An open study of triiodothyronine augmentation of selective serotonin reuptake inhibitors in treatment-resistant major depressive disorder
    Dan V Iosifescu
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA
    J Clin Psychiatry 66:1038-42. 2005
    ..In an open trial, we investigated the efficacy of triiodothyronine (T(3)) adjuvant to selective serotonin reuptake inhibitors (SSRIs) in subjects with major depressive disorder (MDD) resistant to SSRI treatment...
  76. ncbi Cardiovascular risk factors may moderate pharmacological treatment effects in major depressive disorder
    Dan V Iosifescu
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Psychosom Med 67:703-6. 2005
    ..In this study, we measured the impact of cardiovascular risk factors on the outcome of antidepressant treatment in major depressive disorder (MDD)...
  77. ncbi Somatic symptoms in outpatients with major depressive disorder treated with fluoxetine
    John W Denninger
    Massachusetts General Hospital, Depression Clinical and Research Program, Dept of Psychiatry, 50 Staniford St, Suite 401, Boston, MA 02114 2541, USA
    Psychosomatics 47:348-52. 2006
    ..Taken together, these findings suggest that developing treatment strategies that successfully target somatic symptoms of depression may further improve the ability to treat depression to remission...
  78. ncbi Low-dose transdermal testosterone augmentation therapy improves depression severity in women
    Karen K Miller
    Neurendocrine Research Program in Women s Health, Neuendocrine Unit, Massachusetts General Hospital, Boston, MA, USA
    CNS Spectr 14:688-94. 2009
    ..However, the effects of low-dose testosterone as augmentation therapy in women with treatment-resistant depression have not been studied...
  79. pmc A double-blind, randomized controlled trial of ethyl-eicosapentaenoate for major depressive disorder
    David Mischoulon
    Massachusetts General Hospital, Depression Clinical and Research Program, Boston, MA 02114, USA
    J Clin Psychiatry 70:1636-44. 2009
    ..To examine the efficacy and tolerability of ethyl-eicosapentaenoate (EPA-E) monotherapy for major depressive disorder (MDD)...
  80. ncbi Treatment-resistant depression and Axis II comorbidity
    Timothy Petersen
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, Mass 02114, USA
    Psychother Psychosom 71:269-74. 2002
    ....
  81. ncbi NEO-FFI factor scores as predictors of clinical response to fluoxetine in depressed outpatients
    Timothy Petersen
    Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, 15 Parkman Street, WAC 812, MA, Boston 02114, USA
    Psychiatry Res 109:9-16. 2002
    ....
  82. pmc A detailed examination of cytokine abnormalities in Major Depressive Disorder
    N M Simon
    Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Eur Neuropsychopharmacol 18:230-3. 2008
    ..These data support a generalized chronic inflammatory state in MDD, and implicate additional cytokines and chemokines previously linked to cardiovascular disease...
  83. doi Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder
    Y Levkovitz
    Psychiatry Department, Shalvata Mental Health Center, Tel Aviv University, Hamargoa 4, POB 94, Tel Aviv, Israel
    Eur Psychiatry 27:518-21. 2012
    ....
  84. doi SAMe and sexual functioning
    C M Dording
    Depression Clinical and Research Program, Massachusetts General Hospital, Department of Psychiatry, Massachusetts General Hospital, 1 Bowdoin Square, 6th Floor, Boston, MA 02114, USA
    Eur Psychiatry 27:451-4. 2012
    ..Consequently, it is vital to develop novel treatments that target antidepressant-induced sexual dysfunction...
  85. ncbi Symptoms of fatigue and sleepiness in major depressive disorder
    David S Baldwin
    Faculty of Medicine, Health, and Life Sciences, University of Southampton, UK
    J Clin Psychiatry 67:9-15. 2006
    ....
  86. ncbi Clinical characteristics of depressed patients with comorbid diabetes mellitus
    Timothy Petersen
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Int Clin Psychopharmacol 21:43-7. 2006
    ..These findings suggest that depressed diabetic patients are more similar than not to non-diabetic depressed patients, although important differences exist...
  87. ncbi A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment
    Maurizio Fava
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA
    J Clin Psychiatry 67:1754-9. 2006
    ..The purpose of the present work is to examine cross-sectionally the prevalence of cognitive and physical side effects of antidepressants during long-term treatment of depression...
  88. ncbi Nortriptyline for treatment-resistant depression
    Andrew A Nierenberg
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, 02114, USA
    J Clin Psychiatry 64:35-9. 2003
    ..This study assesses the efficacy of nortriptyline for patients with treatment-resistant major depression...
  89. ncbi Early-onset depression and the emotional and behavioral characteristics of offspring
    Timothy J Petersen
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Depress Anxiety 18:104-8. 2003
    ..This finding may be significant in uncovering sources of vulnerability and formulating intervention strategies for offspring of depressed parents...
  90. ncbi Comorbid medical illness and relapse of major depressive disorder in the continuation phase of treatment
    Dan V Iosifescu
    Depression Clinical and Research Program, Psychiatry Department, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
    Psychosomatics 45:419-25. 2004
    ..Greater medical comorbidity was also associated with higher increases in self-reported symptoms of depression, anxiety, and anger during the follow-up...
  91. ncbi Treatment-resistant depression
    Daniel Souery
    Department of Psychiatry, Erasme Hospital, Universite Libre de Bruxelles, Brussels, Belgium
    J Clin Psychiatry 67:16-22. 2006
    ..However, the optimal strategy for treating TRD has yet to be identified. Therefore, further controlled clinical trials are essential to identify the most effective treatment strategies...
  92. ncbi Extreme response style in recurrent and chronically depressed patients: change with antidepressant administration and stability during continuation treatment
    Timothy J Peterson
    Rhode Island Hospital Department of Psychiatry, Mood Disorders Program, Providence, RI 02903, USA
    J Consult Clin Psychol 75:145-53. 2007
    ..These results are consistent with recent findings suggesting that metacognitive factors may be as important as changes in thought content when treating depression...

Research Grants4

  1. 1/2-Ziprasidone Augmentation of SSRIs for Treatment-Resistant Depression (TRD)
    George Papakostas; Fiscal Year: 2009
    ..We estimate that 180 of these patients will enter the double-blind phase. ..
  2. 1/2-Ziprasidone Augmentation of SSRIs for Treatment-Resistant Depression (TRD)
    George I Papakostas; Fiscal Year: 2010
    ..We estimate that 180 of these patients will enter the double-blind phase. ..